AstraZeneca has agreed to sell certain rights to Nexium and Vimovo to Grunenthal, banking $815m upfront to boost the balance sheet and help fund development in its three main therapy areas.
AstraZeneca PLC is continuing to clear out non-core assets and by selling to Grunenthal GMBH the European rights to its proton pump inhibitor Nexium (esomeprazole), which reduces stomach acid, it is starting to say goodbye to one of its most iconic brands and former growth drivers.
The privately owned German group is paying $700m up front to bag the European prescription medicine rights to Nexium, plus...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
